Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"
Tournilhac, O; Hacini, M; Bouabdallah, K; Laribi, K; Maerevoet, M; Ysebaert, L; Guidez, S; Le Gouill, S; Andre, M; Dupuis, J; Thieblemont, C; Bachy, E; Daguindau, N; Morschhauser, F; Tricot, S; Feugier, P; Banos, A; De la Chapelle, TL; Chauchet, A; Gyan, E; Cartron, G; Farhat, H; Camus, V; Drenou, B; Zerazhi, H; Sibon, D; Nicolas-Virelizier, E; Delette, C; Snauwaert, S; Straetmans, N; Delarue, R; Parrens, M; Bossard, C; De Leval, L; Gaulard, P; Damaj, GL
BLOOD, 2020; 136 ():
